Avara Pharmaceutical Services acquires Sterile facility from Pfizer in Italy
Avara Pharmaceutical Services has signed an agreement with Pfizer Inc. to acquire the Liscate, Italy sterile manufacturing facility. “This acquisition is an important component of our strategic plan and expands our services by adding sterile processing capability, which is in very high demand,” stated Timothy C. Tyson, Chairman and CEO.
Avara Pharmaceutical Services is a state-of-the-art contract manufacturing and technical services organization providing both API formulation and manufacturing, along with secondary formulation, manufacturing and packaging of small molecule drugs, including highly potent compounds. Avara has secondary manufacturing technologies including granulation, coating, blending, encapsulation, compression and drying of tablets and capsules.
Avara Pharmaceutical Services now has six sites. Two in the US, including the corporate HQs; one in Puerto Rico, one in the UK, one in Ireland and this new additional site in Italy.
- Norwalk, CT (USA) – Corporate HQ
- Arecibo, Puerto Rico -Secondary manufacturing and packaging
- Shannon, Ireland -API formulation and manufacturing
- Norman, OK (USA) -Secondary manufacturing and packaging
- Avlon, United Kingdom –API formulation and manufacturing
- Liscate, Italy-Sterile Manufacturing
“As we celebrate another important milestone, we continue with great confidence to build a pharmaceutical services company with complementary offerings in key regions in this rapidly growing market. Each site has significant professional experience, state of the art capability and a long history of delivering high quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements in every major market around the world. The people who are a part of the Avara team are the key to our long-term success,” said Tyson. “We are focused on delivering on our commitments and earning the trust of every customer we deal with.”